Share Name Share Symbol Market Type Share ISIN Share Description
Verseon Corporation LSE:VERS London Ordinary Share COM USD0.001 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 50.50p 50.00p 51.00p 50.50p 49.30p 49.30p 0 08:00:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -15.1 -9.6 - 80.56

Verseon Corporation Result of Subscription & Related Party Transaction

19/03/2019 7:01am

UK Regulatory (RNS & others)

Verseon (LSE:VERS)
Historical Stock Chart

3 Months : From Feb 2019 to May 2019

Click Here for more Verseon Charts.


RNS Number : 2285T

Verseon Corporation

19 March 2019


March 19, 2019

Verseon Corporation

("Verseon" or the "Company")

Result of Subscription and Related Party Transaction

FREMONT, Calif.-Further to its announcement released on March 18, 2019, Verseon, the clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, is pleased to announce it has raised US$ 10.7 million (the "Subscription") through the issue of 7,700,000 new common shares (the "Subscription Shares") at 105 pence per share ("Subscription Price") to existing shareholders.

The participation in the Subscription of Woodford Investment Management Limited, a substantial shareholder in Verseon, constitutes a related party transaction under Rule 13 of the AIM Rules. Woodford Investment Management purchased 7,500,000 of the Subscription Shares. The directors of the Company, having consulted with Arden Partners plc in its capacity as the Company's nominated adviser for the purposes of the AIM Rules, consider the terms of the transaction to be fair and reasonable insofar as the Company's shareholders are concerned.

An application has been made for the 7,700,000 Subscription Shares to be admitted to trading on AIM. Admission is expected to occur on March 22, 2019. Following Admission, the Company will have 159,399,413 common shares admitted to trading on AIM with 42,917 common shares held in Treasury. Therefore, the total number of voting rights in the Company will be 159,356,496. This figure that may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in or a change to their interest in the Company under the Disclosure Guidance and Transparency Rules of the UK Financial Conduct Authority.

About Verseon

Verseon Corporation (AIM: VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Find us on Twitter and LinkedIn.

- Ends -

For further information, please contact:

 Verseon Corporation               
 Sebastian Wykeham / Tina Schlafly          +1 (510) 225 9000 
 Arden Partners (NOMAD and Joint Broker) 
 Ruari McGirr / Ciaran Walsh / Alex          +44 (0) 20 7614 
  Penney                                      5900 
 Cantor Fitzgerald Europe (Joint Broker) 
                                            +44 (0) 20 7894 
 Phil Davies                                 7000 

For financial and business media enquiries, please contact

 Buchanan Communications Ltd (PR Advisers) 
                                              +44 (0) 20 7466 
 Henry Harrison-Topham / Jamie Hooper          5000 

For trade and pharma media enquiries, please contact

 Vane Percy & Roberts 
                         +44 (0) 1737 821 
 Simon Vane Percy         890 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

March 19, 2019 03:01 ET (07:01 GMT)

1 Year Verseon Chart

1 Year Verseon Chart

1 Month Verseon Chart

1 Month Verseon Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190521 08:39:58